Sierra Capital’s Maravai LifeSciences MRVI Stock Holding History

Sierra Capital’s Portfolio MRVI Stock Details MRVI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-310	Closed	-$11K	–	797
2022 Q1	$11K	Sell	310 -46	-13%	-$1.54K	﹤0.01%	469
2021 Q4	$15K	Buy	+356	New	+$14.4K	﹤0.01%	440

Other funds holding MRVI

GTCR LLC Chicago, Illinois $3.78B AUM 27.82% 1-Year Est. Return

Select Equity Group New York $19.5B AUM 17.33% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

OCBV

Ownership Capital B.V. Amsterdam, Netherlands $178M AUM 4.75% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Sierra Capital's MRVI Position: Q2 2022 in Review

Sierra Capital sold out of Maravai LifeSciences (MRVI) in Q2 2022, closing a stake of 310 shares — an estimated $11K sold.

Sierra Capital first reported a position in MRVI in Q4 2021 and held it in 2 quarters. The position peaked at $15K in Q4 2021. 216 funds tracked by Wall St. Rank hold MRVI as of Q2 2022.

Sierra Capital reported no remaining Maravai LifeSciences position as of Q2 2022 after selling out during the quarter.
Sierra Capital sold 310 Maravai LifeSciences shares in Q2 2022, an estimated $11K.
Sierra Capital first reported a position in Maravai LifeSciences in Q4 2021 and held it in 2 quarters.
Sierra Capital's Maravai LifeSciences position peaked at $15K in Q4 2021.
216 funds tracked by Wall St. Rank held Maravai LifeSciences as of Q2 2022.

Based on Sierra Capital's 13F filing for Q2 2022, filed 4 Aug 2022.